Suits Over Fosamax Link to Femur Fractures Get New Life
The U.S. Court of Appeals for the Third Circuit has overturned the dismissal of multidistrict litigation over femur fractures suffered by users of Merck's osteoporosis drug Fosamax. The decision gives new life to about 5,000 cases that had been dismissed in federal and state courts, according to plaintiffs' counsel.
This premium content is reserved for New Jersey Law Journal subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now